Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody.
about
Systemic delivery of oncolytic viruses: hopes and hurdlesNatural antibody and complement mediate neutralization of influenza virus in the absence of prior immunityIgG in cervicovaginal mucus traps HSV and prevents vaginal herpes infectionsComplement Evasion Strategies of Viruses: An Overview.Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.Herpes simplex virus type 2 glycoprotein E is required for efficient virus spread from epithelial cells to neurons and for targeting viral proteins from the neuron cell body into axons.Genetic variants of innate immune receptors and infections after liver transplantation.Complement and viral pathogenesisPoxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein.Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs.A new method for the detection of neutralizing antibodies against mumps virus.Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compaEvasion of early antiviral responses by herpes simplex viruses.A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell ImmunogensThe challenge of developing a herpes simplex virus 2 vaccine.Distribution characteristics of DNA vaccine encoded with glycoprotein C from Anatid herpesvirus 1 with chitosan and liposome as deliver carrier in ducks.A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.Complement Opsonization Promotes Herpes Simplex Virus 2 Infection of Human Dendritic Cells.Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanismHerpes simplex virus 1 ICP22 but not US 1.5 is required for efficient acute replication in mice and VICE domain formation.Herpes simplex virus as a tool to define the role of complement in the immune response to peripheral infection.Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides.Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.Oncolytic herpes simplex virus interactions with the host immune system.Completely assembled virus particles detected by transmission electron microscopy in proximal and mid-axons of neurons infected with herpes simplex virus type 1, herpes simplex virus type 2 and pseudorabies virusCell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack.Genome-wide association study (GWAS) of human host factors influencing viral severity of herpes simplex virus type 2 (HSV-2).
P2860
Q21284969-9B454E57-C5C9-443A-9ACD-B848435DCF27Q24672388-279108C5-4DD5-443B-A868-6A6ADF9D2774Q30585914-1821C5CB-FC49-4DDD-86F9-2ED9BA486B83Q33804431-BFF299C4-1DE8-49EC-BB7A-A49370A652ECQ34057952-D21E08B5-DB49-4DD6-85B8-8F556596513CQ34071917-8F89751E-74FF-458E-8373-B5C139B62F17Q34093766-84421620-3F2B-4048-8CFB-5D6334A59130Q34162421-BBECF87B-D5DE-4C1F-A4BE-7E4991A2A660Q34190609-E4760D80-92B5-4B28-A8BF-27926717A36CQ34229689-9B1F2F48-F436-499C-9FF3-BDFE121189FDQ34549656-0FFA3734-2CF5-4533-93AF-E0C30955AABBQ34825222-5ECA1376-4B29-42C6-BB44-73C01BA525CAQ35275146-C85FD6A9-FC47-450D-A90F-13BFC1AF77E4Q35414669-C1EA8B0F-90D7-48F6-A7EC-02FDE3AE4FC3Q35914367-343083BF-4578-48D7-890E-22473A5662C0Q36671106-66990B05-F050-4EEE-AFF2-47812A644EF6Q36741202-C064EF15-440C-4D6D-A6CA-A9BE92A839F0Q36845870-2D6E6632-6E44-4415-B043-B698DE4136EAQ36878921-A81D7108-2376-44C0-9CFF-3C132C729292Q36898823-02627617-F189-470A-8EA8-CE916926E249Q37336866-43C6661B-AFF8-48B5-AAEF-65C801BEB789Q37456642-8C34A76C-8D3C-4F32-A407-A11C41881760Q37547107-706B40A3-DAB9-4685-BD5E-664830D2AD21Q38160482-48DD5157-BA42-4053-B78A-343A94BEC1A5Q38241377-1BD63544-88D0-4D67-AB44-73EFEA40E7BAQ38920459-1BB7D4C6-2DDA-4022-8374-BFD43E3C5D9DQ39637899-ABDCE663-0529-465D-BDE7-AC8871F5804AQ40011089-0A4A0065-2F94-4D05-A0DD-02265373E9B6Q52657294-F6C7488C-56EF-43C5-A01C-A5D15338DDFF
P2860
Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Herpes simplex virus type 1 an ...... ral immunoglobulin M antibody.
@ast
Herpes simplex virus type 1 an ...... ral immunoglobulin M antibody.
@en
Herpes simplex virus type 1 an ...... ral immunoglobulin M antibody.
@nl
type
label
Herpes simplex virus type 1 an ...... ral immunoglobulin M antibody.
@ast
Herpes simplex virus type 1 an ...... ral immunoglobulin M antibody.
@en
Herpes simplex virus type 1 an ...... ral immunoglobulin M antibody.
@nl
prefLabel
Herpes simplex virus type 1 an ...... ral immunoglobulin M antibody.
@ast
Herpes simplex virus type 1 an ...... ral immunoglobulin M antibody.
@en
Herpes simplex virus type 1 an ...... ral immunoglobulin M antibody.
@nl
P2093
P2860
P1433
P1476
Herpes simplex virus type 1 an ...... ural immunoglobulin M antibody
@en
P2093
Harvey M Friedman
John M Lubinski
Michael K Pangburn
Ming Jiang
P2860
P304
P356
10.1128/JVI.80.8.4038-4046.2006
P407
P577
2006-04-01T00:00:00Z